Condition: Breast Cancer · Neoadjuvant · HER2-positive Breast Cancer · Sponsor: The First Affiliated Hospital with Nanjing Medical University
1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population; 2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.
This description comes directly from the study's public registry record.
Zhihone Zhang, Doctor of Medicine · 18013348615 · zhangzhih2001@aliyun.com
Jing Wu, Doctor of Medicine · 18013348615
Always discuss trial participation with your own doctor first.
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06479460